Aequorea Vision Medical

Aequorea Vision Medical is commercializing a breakthrough medical technology that will revolutionize the diagnosis and treatment of Human Papillomavirus (HPV), Bovine Papillomavirus (BPV), and potentially cervical cancer.

• The number of women affected by cervical cancer is growing worldwide. Cervical cancer is currently the second most common cancer in women, and yet it is a preventable disease.
• Bovine Papillomavirus (BPV) is highly prevalent among cattle and is the known cause for Equine Sarcoids. If animals with BPV are left untreated, they risk the chance of developing cancer or spreading the virus to other animals.

AVM™ SureScreen System allows physicians and veterinarians to SEE AND TREAT, meaning that they can visually identify and instantaneously treat cells damaged by HPV (the now known cause of cervical cancer) and treat animals infected by BPV before cells have the opportunity to become life threatening.

Aequorea Vision Medical is dedicated to revolutionizing cervical cancer and BPV screening tests. With AVM™ SureScreen technology we have the potential to save billions of dollars and millions of lives.

Our History

Faced with the realization that far too many women were dying from advanced cervical cancer, the inventors of AVM™ SureScreen technology began an intensive search for alternatives to what was then the accepted standard of care. Though the accepted standard was credited with having saved millions of lives, there was no doubt that it also was failing millions more. For many reasons, scientific and circumstantial, the standard of care was failing to detect pre-cancerous conditions for an unacceptably large segment of the world female population. This was especially true for the millions of women who live their lives oblivious to the value of regular screening for Human Papilloma viral infection. Legions of them, even if they were to submit to a single visit to a physician’s office, were in no way prepared to adhere to a standard of care that would require repeated visits. The only way to change the deadly outcomes for so many of these women was to develop a less invasive, more immediate, simpler to use, and more reliable level of care.

Many years of research, testing, and a substantial financial commitment have led to development of the AVM™ SureScreen System. The original focus and motivation has never changed, to empower health care professionals, no matter where they are working, with a simple, efficacious, reliable, affordable set of tools to intervene early enough to improve the health and extend the lives of millions of women.

In 2002 medical researchers discovered there was a more than 99% causal link between persistent HPV infection and cervical cancer. HPV was THE cause of cervical cancer. AVM used its medical and optical research expertise to move forward with its vision, to develop a means for identifying HPV. AVM’s first generation device was capable of visually identifying an HPV infection in women during a single routine pelvic exam, and continuous improvements to this system are producing ever more promising applications.

Through a partnership of medical, optical, and financial professionals, AVM has developed the AVM™ SureScreen System. This partnership now is being expanded to greatly enhance our capabilities. We are moving ever closer to realization of the original vision. We are closing in on the day when millions of women in any part of the planet might soon be freed from the tragic prospect that they might have died from a disease that is both one of the world’s most deadly and one of its most easily preventable.

Currently this technology for diagnosing HPV is secured, and is being used in Mexico City clinics. These machines are proving that our technology is nearly 100% accurate in diagnosing HPV infection in all stages.

To learn more about AVM™ SureScreen devices, please CONTACT US.